ObjectiveTo investigate the influence of strengthening intervention on antiviral treatment compliance for cirrhosis patients following chronic hepatitis B. MethodsOne hundred patients with cirrhosis following chronic hepatitis B undergoing antiviral treatment between January 2007 and January 2009 were randomly divided into intervention group and control group with 50 patients in each group.Patients in the control group received routine care.For patients in the intervention group,besides routine care,strengthening education on the disease,medication guide,and weekly telephone follow-up after discharge were also added.On the time points of 6,12,18,24,30,36 months after patients were discharged,we followed them up with self-designed questionnaire,and compared the two groups of patients on the rates of fully complying with doctors,not fully complying with doctors and completely not complying with doctors.And the reasons were also analyzed. ResultsEighteen months after being discharged,the two groups had no significant difference in the rate of complying with doctors (P>0.05),while the difference was significant 24,30,36 months after leaving the hospital (P<0.05).The reasons were not following the doctors were mainly high cost and unsatisfying treatment effect.In the control group,the reasons also included lack of knowledge about the disease and lack of guidance and supervision. ConclusionThrough strengthening nursing intervention,patients'treatment compliance can be improved significantly.
ObjectiveTo investigate the psychological status of patients with chronic hepatitis B during the anti-virus treatment. MethodThe questionnaires of 150 outpatients with chronic hepatitis B treated between May 2013 and May 2014 were collected. And the date was properly processed. ResultsAll the patients were suffering from different degrees of worries, and the top 3 rates of worries were:the recurrence after stop using drugs (88.00%), the side effects of long-term medication (78.00%) and discrimination from people seeing the package of drugs (69.33%). ConclusionsPatients with chronic hepatitis B are in different degrees of psychological hazard during the treatment of anti-virus; further nursing work in psychological counseling and health education are needed to eliminate the hidden trouble, as to enhance the curative effect.
目的:分析艾滋病患者抗病毒治療后的臨床療效,比較不同基線CD4+T淋巴細胞計數增長情況。方法:納入51例符合治療標準的初治患者,采用國家標準抗病毒治療一線方案和衛生部統一提供的免費藥物,通過對服藥后半月、1月、3月、6月、12月的時段進行臨床評估和實驗室檢查,并比較不同基線CD4+T淋巴細胞計數水平治療后的增長情況。結果:治療12月后,各方案組療效無差異,不同基線CD4+T淋巴細胞計數的增長有顯著差異。毒副反應為肝損傷、過敏性皮疹,消化道反應為主。結論:HAART可顯著的抑制體內HIV病毒的復制,重建機體的免疫功能,緩解患者病情,有利于存活期的延長。嚴重的毒副作用發生較少。
【摘要】 目的 研究納米銀體外抗H3N2流感病毒的作用，并初步探索其作用機制。 方法 在H3N2流感病毒吸附細胞后加入納米銀和吸附前用納米銀預處理犬腎細胞（MDCK），在體外用細胞病變效應（cytopathic effect，CPE）觀察法和3-（4，5-二甲基-2-噻唑）-2，5-二苯基溴化四唑（3-（4，5-dimethylthiazol-2-yl）-2，5-diphenyltetrazolium bromide，MTT）測值法，分析納米銀對H3N2流感病毒感染MDCK細胞的預防作用、直接滅活作用以及對流感病毒子代病毒體生成的抑制作用，運用RT-PCR法研究納米銀對H3N2流感病毒HA基因復制的干擾作用。 結果 納米銀能明顯殺傷H3N2流感病毒，50、25 μg/mL的納米銀溶液與H3N2流感病毒充分作用2 h后感染MDCK細胞，細胞存活率分別為94.38%和92.17%，納米銀能有效抑制流感病毒對MDCK細胞的侵入和侵入后病毒的繼續增殖，25 μg/mL納米銀溶液通過上述兩種方式處理細胞，細胞存活率分別為85.39%和83.28%，與病毒對照組相比，差異均有統計學意義（Plt;0.001）；400、200 μg/mL納米銀溶液分別與流感病毒H3N2充分混合作用15、30、60、120 min后，病毒液的HA基因均未能成功擴增，純病毒液和溶劑對照組在1 700 bp處均出現明顯條帶。 結論 通過3種不同的給藥方式，納米銀在體外均能明顯抑制流感病毒對細胞的感染，納米銀抑制流感病毒的機制可能是通過干擾H3N2流感病毒和吸附、穿入和基因的復制，從而抑制子代病毒體的生成。【Abstract】 Objective To explore the anti-viral effects of silver-nanoparticles (silver-nps) on H3N2 influenza virus in vitro and to evaluate its mechanism. Methods Silver-nps was added to canine kidney cells (MDCK) before and after the cells was adsorpted by H3N2 influenza virus. Cytopathic effect (CPE) assay and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay were used to analyze the preventive effect, directly off deactivation, and the inhibit formation of progeny virions of silver-nps on H3N2 viruses. The interference of HA gene replication was observed by the RT-PCR assay. Results The survival rate of MDCK cells was 94.38% and 92.17% after 50 and 25 μg/mL silver-nps were mixed with 100 TCID50 H3N2 virus in 2 hours, and the survival rate of MDCK cells was 85.39% and 83.28% before and after the cells was adsorpted by H3N2 influenza virus when 25 μg/mL silver-nps was added to the cells (all compared to virus control, Plt;0.001), which showed that silver-nps could inactivate H3N2 virus, prevente them invasing to the cells and reproducting when H3N2 entered the cell remarkedly. The HA gene was not amplified successfully when 50 and 25 μg/mL silver-nps were mixed with 100TCID50 H3N2 virus in 15, 30, 60, and 120 minutes later, but both pure virus solution and solvent control group appeared a significant bright band in the 1 700 bp area. Conclusion Under three different administration modes, silver-nps has an obvious effect against H3N2 in vitro, which could interfere the HA gene replication and inhibit the formation of H3N2 progeny virions.
ObjectiveTo summarize progress of 25-hydroxycholesterol (25-OHC), 27-hydroxycholesterol(27-OHC), and 7α,25-hydroxycholesterol (7α,25-OHC) three oxidized cholesterols in inflammation and immunology and to provide evidence for related basic researches and diseases treatments.MethodThe relevant literatures about these three important oxidized cholesterols in the inflammation and immunology in recent years were reviewed.ResultsThe 25-OHC and 27-OHC could exert the antiviral effects by interfering with various viruses invading the host via various mechanisms. Moreover, the 25-OHC and 27-OHC also played the important regulatory roles in a variety of inflammatory processes and inflammatory diseases. The 7α,25-OHC played the important role in a variety of inflammatory processes by acting on the inflammatory and immune cell membrane receptor G-protein coupled receptor 183 (also known as Epstein-Barr virus-inducible receptor 2).Conclusion25-OHC, 27-OHC and 7α,25-OHC play an important roles in occurrence and development of various inflammatory and immune responses and diseases of inflammatory and immune by acting on a variety of nuclear receptors and membrane receptors.
Objective To analyze the clinical characteristics of adverse drug reaction (ADR) caused by 3 kinds of coronavirus disease 2019 drugs, and provide a reference for clinical safe medication. MethodsA total of 33 patients with coronavirus disease 2019 admitted to Xiangtan Central Hospital from January 20 to March 5, 2020 were selected as the research objects. The clinical data of patients with ADR during the antiviral process were analyzed retrospectively. The patients’ gender, age, type of medication, combination medication, organs or systems involved, and clinical manifestations were summarized and analyzed. Results A total of 33 patients were enrolled. A total of 21 cases of ADR were reported. The incidence of ADR is higher in patients older than 60 years (80.0%). The most common clinical manifestations are digestive tract symptoms (66.7%). The incidence of ADR is highest in the combination of lopinavir/ritonavir+arbidol+ribavirin (100.0%), followed by the combination of lopinavir/ritonavir+arbidol (85.7%). Abidol and ribavirin each caused 1 case of severe ADR. Conclusion For patients with coronavirus disease 2019, the combination of two or more antiviral drugs should be avoided, and pharmaceutical monitoring should be strengthened for elderly, severe/critical and allergic patients.
ObjectivesTo assess the efficacy and safety of corticosteroid and antiviral agents for idiopathic facial nerve paralysis (IFNP) by network meta-analysis.MethodsPubMed, EMbase, The Cochrane Library, CBM, CNKI, WangFang Data and VIP databases were electronically searched to collect randomized controlled trials (RCTs) of corticosteroid and antiviral agents for IFNP from inception to January 31th, 2018. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. The meta-analysis was performed by R 3.3.3 and Stata 13.0 software.ResultsA total of 16 RCTs involving 3 061 patients were included. The results of network meta-analysis showed that: for the facial function recovery rates, corticosteroid plus antiviral agents was superior to placebo and antiviral agents alone at 3-month follow-up. Corticosteroid plus antiviral agents was superior to placebo, antiviral agents or corticosteroid alone at 6-month follow-up (if the satisfactory recovery was defined as a House-Brackmann grade class Ⅱ or below). When the follow-up exceeded 6 months, corticosteroid alone was superior to placebo and antiviral agents alone, corticosteroid plus antiviral agents was superior to placebo and antiviral agents alone. All of the differences above were statistically significant. For the sequelae, corticosteroid plus antiviral agents and corticosteroid alone were superior to placebo and antiviral agents alone. Corticosteroid plus antiviral agents was superior to corticosteroid alone. The differences were statistically significant. For the adverse events, there were no significant differences between any other pairwise comparisons of these different interventions.ConclusionConsidering the efficacy and safety, patients with IFNP treated corticosteroid plus antiviral agents are more likely to have a better recovery of facial function and less likely to develop sequelae, followed by corticosteroid alone. More high-quality, large scaled and multicenter RCTs are required to verify the conclusions above, and focus on the treatment of children and patients with severe facial paralysis.
At present, the most commonly used nucleoside (acid) anaog (NAs) treatment regimen in clinical practice cannot completely cure chronic viral hepatitis B (CHB). However, although the polyethylene glycol interferon treatment regimen is superior to the NAs regimen in terms of immune mechanism, it has the disadvantage of low hepatitis B virus DNA response rate. In recent years, the cure of CHB is being studied all over the world. Various mechanisms and drug targets are being explored, and diversified therapeutic strategies are also being used. Clinical cure of hepatitis B is possible, but it is still in the early stage, and many potential drugs and better therapeutic strategies are still being tested. This article mainly reviews the latest progress in the treatment of CHB based on the recent research achievements in direct antiviral drugs and host immunotherapy as well as the research progress in combination therapy.